Benign Gallbladder DiseaseNCT02485392
A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder
A study testing Da Vinci Single Site Robot-Assisted Cholecystectomy and Single Incision Laparoscopic Cholecystectomy in people with Benign Gallbladder Disease, run by Kantonsspital Winterthur KSW at 1 site in Switzerland.
Trial summary
A single-blinded randomized clinical trial (RCT) designed to compare Single-Site robot-assisted with single-incision laparoscopic cholecystectomy. The study directly compares both surgical approaches in a cohort of 60 patients (30 patients in each arm) with benign gallbladder disease from the Department of Surgery at… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Benign Gallbladder Disease
- What is being tested?
- Da Vinci Single Site Robot-Assisted Cholecystectomy and Single Incision Laparoscopic Cholecystectomy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jul 2015to Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient compliance and geographic proximity allow proper preoperative checkup and postoperative follow-up
- Written informed consent given by the patient
- Women who are not breastfeeding and are not pregnant
- Age ≥18 years
- Symptomatic cholecystolithiasis
- Chronic cholecystitis
- Benign gallbladder polyps
Who cannot join
- Significant concomitant diseases making the patient unsuitable for abdominal surgery by the judgement of the physicians involved
- Peritoneal carcinomatosis or other extensive metastatic disease
- American Society of Anesthesiologists (ASA) IV and V patients
- Mental or organic disorders which could interfere with giving informed consent or receiving treatments
- Contraindications to pneumoperitoneum
- Suspicion of malignant disease
Show all 10Show fewer
- Previous extensive upper abdominal surgery
- Acute cholecystitis
- Emergency cholecystectomy
- Obesity II°---III° (BMI>35.0 kg/m2)
Trial locations and contacts
1 site in 1 country.
About this study
A single-blinded randomized clinical trial (RCT) designed to compare Single-Site robot-assisted with single-incision laparoscopic cholecystectomy. The study directly compares both surgical approaches in a cohort of 60 patients (30 patients in each arm) with benign gallbladder disease from the Department of Surgery at the Cantonal Hospital of Winterthur (Kantonsspital Winterthur) in Switzerland. The primary endpoint of the study is the surgeon's physical and mental stress load at the time of surgery and is assessed by validated Local Experienced Discomfort (LED) and Subjective Mental Effort Questionnaire (SMEQ) visual analogue scales. The secondary endpoints include costs of the procedure, intra-operative blood loss, operating time, intra-operative conversion rate and additional trocar placement, complications, length of hospital stay, Health-Related Quality of Life (HRQoL) and cosmesis. HRQoL and cosmesis will be assessed using the validated Gastrointestinal Quality of Life Index (GIQLI) and the Body Image Questionnaires (BIQ), respectively. The inclusion criteria cover most notably symptomatic cholecystolithiasis, chronic cholecystitis, benign gallbladder polyps and age ≥18 years. The exclusion criteria are, among others, acute cholecystitis, emergency cholecystectomy, previous extensive upper abdominal surgery and suspicion of malignant disease. Non-stratified block randomization (random block sizes 2 and 4) will be used to achieve balance in the allocation of participants to both treatments arms and prevent a premature decoding of the randomization scheme. Hereby, the patient will not be informed about the group assignment until the last outpatient follow-up and only after he/she has completed and returned all required questionnaires (GIQLI and BIQ). The operation will be performed according to the group assignment by senior surgeons only who have a wide experience in both robotic Single-Site and conventional single-incision laparoscopy. All data are recorded safely using the SecuTrialTM program. Sample-size calculations are based on the results of the previously mentioned experimental setup by Schatte et al, utilizing an estimated effect size of 0.8, at a power of 0.8 and an alpha-error level of 0.05, as well as considering a potential additional error margin of 10-15% of the calculations (G-Power 3.1 software, Heinrich-Heine University Duesseldorf/Germany). The estimated total duration of the study is 1.5 years, including the scheduled 1-month and 1-year postoperative follow-up visits. The study will be carried out in accordance with principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by International Conference on Harmonization (ICH), and Swiss regulatory authority's requirements.
- Conditions
- Benign Gallbladder Disease
- Being tested
- Da Vinci Single Site Robot-Assisted Cholecystectomy, Single Incision Laparoscopic Cholecystectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Da Vinci Single Site Robot-Assisted CholecystectomyDevice
Single Incision Laparoscopic CholecystectomyDevice
| Study group | Role | What they receive |
|---|---|---|
| Single-Site robot-assisted cholecystectomy | Active comparator | Single-Site robot-assisted cholecystectomy Receives: Device: Da Vinci Single Site Robot-Assisted Cholecystectomy |
| Single-incision laparoscopic cholecystectomy | Active comparator | Single-incision laparoscopic cholecystectomy Receives: Device: Single Incision Laparoscopic Cholecystectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surgeon's comfort as measured by LED and SMEQ questionnaires
Measured: 1 Day
Secondary outcomes (9)
Intra-operative blood loss
Measured: 1 day
Operating time
Measured: 1 day
Intra--operative conversion rate
Measured: 1 day
Complications
Measured: 1 year
Length of hospital stay
Measured: until discharge (average of 2 days)
Costs of procedure
Measured: until discharge (average of 2 days)
Health--Related Quality of Life (HRQoL)
Measured: 1 year
Cosmesis as measured by Body Image Questionnaire (BIQ)
Measured: 1 year
Intra-operative additional trocar placement
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2015 (estimated)
- Study startJul 2015
- Primary completionJul 2016
- Study completionJul 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Benign Gallbladder DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kantonsspital Winterthur KSW
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stefan Breitenstein, MD, Principal investigator, Kantonsspital Winterthur KSW
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02485392
- Sponsor's protocol ID
- KEK-ZH 2014-0114
- Status last verified
- Sep 2016
- First submitted
- 19 Feb 2015
- Last updated
- 9 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted versus laparoscopic single-incision cholecystectomy: results of a randomized controlled trial. Surg Endosc. 2019 May;33(5):1482-1490. doi: 10.1007/s00464-018-6430-7. Epub 2018 Sep 14.
PubMed 30218263Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted single-site compared with laparoscopic single-incision cholecystectomy for benign gallbladder disease: protocol for a randomized controlled trial. BMC Surg. 2017 Feb 9;17(1):13. doi: 10.1186/s12893-017-0206-1.
PubMed 28183345
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder
- ClinicalTrials.gov ID
- NCT02485392
- Acronym / sponsor ID
- KEK-ZH 2014-0114
- Conditions
- Benign Gallbladder Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Kantonsspital Winterthur KSWUniversity, hospital or other
- Study start
- Jul 2015
- Primary completion
- Jul 2016 (actual)
- Study completion
- Jul 2017 (estimated)
- First posted
- 30 Jun 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A single-blinded randomized clinical trial (RCT) designed to compare Single-Site robot-assisted with single-incision laparoscopic cholecystectomy. The study directly compares both surgical approaches in a cohort of 60 patients (30 patients in each arm) with benign gallbladder disease from the Department of Surgery at the Cantonal Hospital of Winterthur (Kantonsspital Winterthur) in Switzerland. The primary endpoint of the study is the surgeon's physical and mental stress load at the time of surgery and is assessed by validated Local Experienced Discomfort (LED) and Subjective Mental Effort Questionnaire (SMEQ) visual analogue scales. The secondary endpoints include costs of the procedure, intra-operative blood loss, operating time, intra-operative conversion rate and additional trocar placement, complications, length of hospital stay, Health-Related Quality of Life (HRQoL) and cosmesis. HRQoL and cosmesis will be assessed using the validated Gastrointestinal Quality of Life Index (GIQLI) and the Body Image Questionnaires (BIQ), respectively. The inclusion criteria cover most notably symptomatic cholecystolithiasis, chronic cholecystitis, benign gallbladder polyps and age ≥18 years. The exclusion criteria are, among others, acute cholecystitis, emergency cholecystectomy, previous extensive upper abdominal surgery and suspicion of malignant disease. Non-stratified block randomization (random block sizes 2 and 4) will be used to achieve balance in the allocation of participants to both treatments arms and prevent a premature decoding of the randomization scheme. Hereby, the patient will not be informed about the group assignment until the last outpatient follow-up and only after he/she has completed and returned all required questionnaires (GIQLI and BIQ). The operation will be performed according to the group assignment by senior surgeons only who have a wide experience in both robotic Single-Site and conventional single-incision laparoscopy. All data are recorded safely using the SecuTrialTM program. Sample-size calculations are based on the results of the previously mentioned experimental setup by Schatte et al, utilizing an estimated effect size of 0.8, at a power of 0.8 and an alpha-error level of 0.05, as well as considering a potential additional error margin of 10-15% of the calculations (G-Power 3.1 software, Heinrich-Heine University Duesseldorf/Germany). The estimated total duration of the study is 1.5 years, including the scheduled 1-month and 1-year postoperative follow-up visits. The study will be carried out in accordance with principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by International Conference on Harmonization (ICH), and Swiss regulatory authority's requirements.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Single-Site robot-assisted cholecystectomy | Active comparator | Device: Da Vinci Single Site Robot-Assisted CholecystectomySingle-Site robot-assisted cholecystectomy |
| Single-incision laparoscopic cholecystectomy | Active comparator | Device: Single Incision Laparoscopic CholecystectomySingle-incision laparoscopic cholecystectomy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient compliance and geographic proximity allow proper preoperative checkup and postoperative follow-up
- Written informed consent given by the patient
- Women who are not breastfeeding and are not pregnant
- Age ≥18 years
- Symptomatic cholecystolithiasis
Key exclusion criteria (10 listed)
- Significant concomitant diseases making the patient unsuitable for abdominal surgery by the judgement of the physicians involved
- Peritoneal carcinomatosis or other extensive metastatic disease
- American Society of Anesthesiologists (ASA) IV and V patients
- Mental or organic disorders which could interfere with giving informed consent or receiving treatments
- Contraindications to pneumoperitoneum
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Da Vinci Single Site Robot-Assisted Cholecystectomy | Device | Single-Site robot-assisted cholecystectomy |
| Single Incision Laparoscopic Cholecystectomy | Device | Single-incision laparoscopic cholecystectomy |
Primary outcome
Surgeon's comfort as measured by LED and SMEQ questionnaires
Time frame: 1 Day
9 secondary outcomes
Intra-operative blood loss
Time frame: 1 day
Operating time
Time frame: 1 day
Intra--operative conversion rate
Time frame: 1 day
Complications
Time frame: 1 year
Length of hospital stay
Time frame: until discharge (average of 2 days)
Costs of procedure
Time frame: until discharge (average of 2 days)
Health--Related Quality of Life (HRQoL)
Time frame: 1 year
Cosmesis as measured by Body Image Questionnaire (BIQ)
Time frame: 1 year
Intra-operative additional trocar placement
Time frame: 1 day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2016.
- Derived from this study: PubMed 30218263Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted versus laparoscopic single-incision cholecystectomy: results of a randomized controlled trial. Surg Endosc. 2019 May;33(5):1482-1490. doi: 10.1007/s00464-018-6430-7. Epub 2018 Sep 14.
- Derived from this study: PubMed 28183345Grochola LF, Soll C, Zehnder A, Wyss R, Herzog P, Breitenstein S. Robot-assisted single-site compared with laparoscopic single-incision cholecystectomy for benign gallbladder disease: protocol for a randomized controlled trial. BMC Surg. 2017 Feb 9;17(1):13. doi: 10.1186/s12893-017-0206-1.
Related trials for Benign Gallbladder Disease
Recruiting
Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease
Cholecystectomy, Robotic, Cholecystectomy, Laparoscopic
Not yet recruitingObservational study
Endoscopic vs Non-endoscopic Drainage for Benign Gallbladder Diseases in High-risk Patients or Patients Desiring Gallbladder Preservation
Gallbladder Diseases, Cholecystitis, Acute
Recruiting
A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease
Hepatopancreaticobiliary and Foregut Operations
Not yet recruiting
Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Laparoscopic Cholecystectomy
Benign Gallbladder Disease, Laparoscopic Cholecystectomy
Not yet recruitingObservational study
Outcomes After Liver and Biliary Resection at a High-Volume Center
Liver Neoplasms, Hepatobiliary Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stefan Breitenstein, MD principal investigator
Kantonsspital Winterthur KSW
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Da Vinci Single Site Robot-Assisted Cholecystectomy and Single Incision Laparoscopic Cholecystectomy in people with Benign Gallbladder Disease, run by Kantonsspital Winterthur KSW at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surgeon's comfort as measured by LED and SMEQ questionnaires (time frame: 1 Day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02485392, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2016.